pSivida Corp Downgraded by Zacks to “Underperform” (PSDV)
pSivida Corp (NASDAQ:PSDV) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a report issued on Thursday, AnalystRatings.Net reports. They currently have a $2.50 target price on the stock. Zacks‘ price objective points to a potential downside of 5.30% from the company’s current price.
pSivida Corp (NASDAQ:PSDV) remained flat at $2.64 during during mid-day trading trading on Thursday. The stock had a trading volume of 202,592 shares. pSivida Corp has a one year low of $1.17 and a one year high of $4.12. The stock has a 50-day moving average of $3.58 and a 200-day moving average of $3.04. The company’s market cap is $70.7 million.
pSivida Corp (NASDAQ:PSDV) last posted its quarterly earnings results on Wednesday, September 25th. The company reported ($0.17) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.05. The company had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.65 million. On average, analysts predict that pSivida Corp will post $-0.58 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Ladenburg Thalmann cut their price target on shares of pSivida Corp from $5.00 to $2.75 in a research note to investors on Friday, October 18th. They now have a “buy” rating on the stock. Separately, analysts at Northland Capital Partners initiated coverage on shares of pSivida Corp in a research note to investors on Tuesday, October 8th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, analysts at Northland Securities initiated coverage on shares of pSivida Corp in a research note to investors on Monday, October 7th. They set an “outperform” rating on the stock.
pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.